Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells $245,910.24 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 18,672 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $245,910.24. Following the completion of the transaction, the chief financial officer owned 259,840 shares in the company, valued at approximately $3,422,092.80. This trade represents a 6.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kyle Piskel also recently made the following trade(s):

• On Wednesday, February 4th, Kyle Piskel sold 2,145 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.46, for a total transaction of $39,596.70.
• On Monday, January 12th, Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total value of $77,220.00.

Adaptive Biotechnologies Trading Up 5.8%

Adaptive Biotechnologies stock opened at $13.17 on Monday. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12 month low of $6.68 and a 12 month high of $20.76. The stock’s 50 day moving average is $16.55 and its 200-day moving average is $15.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.23) EPS. As a group, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ADPT shares. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Guggenheim raised their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. BTIG Research lifted their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies in the fourth quarter valued at about $28,000. Sound Income Strategies LLC acquired a new stake in Adaptive Biotechnologies during the third quarter worth about $30,000. EverSource Wealth Advisors LLC grew its stake in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares in the last quarter. Assetmark Inc. increased its holdings in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies in the 4th quarter valued at about $51,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.